Clinical Trials Directory

Trials / Conditions / Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity

Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity

18 registered clinical trials studyying Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity.

StatusTrialSponsorPhase
CompletedFiclatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell
NCT03422536
University of ArizonaPhase 2
TerminatedPaclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection
NCT01249443
AIDS Malignancy ConsortiumPhase 1
CompletedCarboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurr
NCT01316757
Fox Chase Cancer CenterPhase 2
CompletedCapecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and Neck
NCT01044433
Abramson Cancer Center at Penn MedicinePhase 2
TerminatedSelenomethionine in Reducing Mucositis in Patients With Locally Advanced Head and Neck Cancer Who Are Receivin
NCT01682031
Roswell Park Cancer InstitutePhase 2
TerminatedSunitinib, Cetuximab, and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Squamous C
NCT00906360
National Cancer Institute (NCI)Phase 1
CompletedBevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Pri
NCT00492089
National Cancer Institute (NCI)Phase 2
CompletedErlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Nec
NCT00397384
National Cancer Institute (NCI)Phase 1
CompletedSunitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer
NCT00387335
National Cancer Institute (NCI)Phase 2
CompletedErlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidne
NCT00101348
National Cancer Institute (NCI)Phase 1 / Phase 2
CompletedLapatinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer
NCT00098631
National Cancer Institute (NCI)Phase 2
CompletedAlvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors
NCT00089362
National Cancer Institute (NCI)Phase 1
TerminatedIntratumoral PV701 in Treating Patients With Advanced or Recurrent Unresectable Squamous Cell Carcinoma of the
NCT00081211
National Cancer Institute (NCI)Phase 1
CompletedBevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
NCT00055913
National Cancer Institute (NCI)Phase 1 / Phase 2
CompletedErlotinib Plus Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Head and Neck Ca
NCT00055770
National Cancer Institute (NCI)Phase 1 / Phase 2
CompletedErlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction
NCT00030498
National Cancer Institute (NCI)Phase 1
Completed7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid
NCT00031681
National Cancer Institute (NCI)Phase 1
CompletedBevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and
NCT00023959
National Cancer Institute (NCI)Phase 1